Effects of Anti-IL5 Biological Treatments on Blood IgE Levels in Severe Asthmatic Patients
Launched by UNIVERSITÀ DEGLI STUDI DI FERRARA · Nov 27, 2019
Trial Information
Current as of May 16, 2025
Completed
Keywords
ClinConnect Summary
Severe asthma, i.e. asthma that is not controlled despite maximal optimized therapy and/or that worsens when high dose treatment is decreased (GINA guidelines - available at https://ginasthma.or), is a major unmet medical need. Major advances in the management of severe asthma occurred in the past few years due to the new targeted biological therapies. Mepolizumab and Benralizumab are humanized monoclonal antibodies able to block interleukin (IL)-5 and the receptor for IL-5, respectively. These biological treatments block the eosinophilic driven inflammation. The effects of these treatments...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • atopy
- • severe eosinophilic asthma (according to GINA guideline - available at https://ginasthma.org)
- • patients treated with monoclonal antibody anti IL-5 (Mepolizumab) or with IL-5 anti-receptor monoclonal antibody (Benralizumab).
- • stable asthma (free from asthma exacerbation for at least 8 weeks)
- Exclusion Criteria:
- • asthma exacerbation in last 8 weeks
- • patients treated for COPD
About Università Degli Studi Di Ferrara
The Università degli Studi di Ferrara, a distinguished Italian institution, is dedicated to advancing medical research and education. With a strong emphasis on interdisciplinary collaboration, the university fosters innovative clinical trials aimed at enhancing patient care and treatment outcomes. Leveraging a robust network of researchers, clinicians, and academic partners, the university is committed to translating scientific discoveries into practical applications that address pressing healthcare challenges. Its focus on ethical standards and rigorous methodologies ensures high-quality research that contributes to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ferrara, , Italy
Foggia, , Italy
Milan, , Italy
Modena, , Italy
Palermo, , Italy
Pordenone, , Italy
Reggio Emilia, , Italy
Verona, , Italy
Patients applied
Trial Officials
Marco Contoli, Prof
Principal Investigator
Università di Ferrara - Azienda Ospedaliero Universitaria di Ferrara
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials